- Home
- IGMS vs GNLX Comparison
IGMS vs GNLX Comparison
Compare IGMS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- GNLX
- Stock Information
- Founded
- IGMS 1993
- GNLX 2001
- Country
- IGMS United States
- GNLX United States
- Employees
- IGMS N/A
- GNLX N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- GNLX Health Care
- Exchange
- IGMS Nasdaq
- GNLX Nasdaq
- Market Cap
- IGMS 82.1M
- GNLX 96.6M
- IPO Year
- IGMS 2019
- GNLX 2023
- Fundamental
- Price
- IGMS $1.17
- GNLX $2.83
- Analyst Decision
- IGMS Hold
- GNLX Strong Buy
- Analyst Count
- IGMS 8
- GNLX 4
- Target Price
- IGMS $6.00
- GNLX $17.75
- AVG Volume (30 Days)
- IGMS 211.8K
- GNLX 157.9K
- Earning Date
- IGMS 08-13-2025
- GNLX 08-13-2025
- Dividend Yield
- IGMS N/A
- GNLX N/A
- EPS Growth
- IGMS N/A
- GNLX N/A
- EPS
- IGMS N/A
- GNLX N/A
- Revenue
- IGMS $2,681,000.00
- GNLX N/A
- Revenue This Year
- IGMS $134.30
- GNLX N/A
- Revenue Next Year
- IGMS $22.37
- GNLX N/A
- P/E Ratio
- IGMS N/A
- GNLX N/A
- Revenue Growth
- IGMS 27.36
- GNLX N/A
- 52 Week Low
- IGMS $0.92
- GNLX $1.60
- 52 Week High
- IGMS $22.50
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- IGMS 42.70
- GNLX 57.73
- Support Level
- IGMS $1.17
- GNLX $2.85
- Resistance Level
- IGMS $1.40
- GNLX $3.29
- Average True Range (ATR)
- IGMS 0.07
- GNLX 0.22
- MACD
- IGMS -0.01
- GNLX 0.06
- Stochastic Oscillator
- IGMS 4.17
- GNLX 64.74
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.